ProQR Therapeutics N.V.
-
Ticker
PRQR
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 51-200 Employees
- Based in Leiden, Netherlands
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of genetic eye diseases such as Leber congenital amaurosis 10, Usher syndrome and autosomal dominant retinitis pigmentosa. Based on their unique proprietary RNA repair platform technologies they are growing their pipeline with patients and loved ones in mind.
REPORT RATINGS
4.8 / 5.0 (45)
ProQR Therapeutics N.V. reports have an aggregate usefulness score of 4.8 based on 45 reviews.
ProQR Therapeutics N.V.
Most Recent Annual Report
MOST RECENT
2023 Annual Report
Older/Archived Annual Reports